JP2015504677A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504677A5 JP2015504677A5 JP2014552323A JP2014552323A JP2015504677A5 JP 2015504677 A5 JP2015504677 A5 JP 2015504677A5 JP 2014552323 A JP2014552323 A JP 2014552323A JP 2014552323 A JP2014552323 A JP 2014552323A JP 2015504677 A5 JP2015504677 A5 JP 2015504677A5
- Authority
- JP
- Japan
- Prior art keywords
- tcf
- biomarker
- level
- subject
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000090 biomarker Substances 0.000 claims 66
- 238000000034 method Methods 0.000 claims 42
- 150000001875 compounds Chemical class 0.000 claims 24
- 239000000523 sample Substances 0.000 claims 22
- 230000001225 therapeutic effect Effects 0.000 claims 20
- 102100035101 Transcription factor 7-like 2 Human genes 0.000 claims 17
- 108010048992 Transcription Factor 4 Proteins 0.000 claims 16
- 102100022108 Aspartyl/asparaginyl beta-hydroxylase Human genes 0.000 claims 15
- 101000901030 Homo sapiens Aspartyl/asparaginyl beta-hydroxylase Proteins 0.000 claims 15
- 101000994437 Homo sapiens Protein jagged-1 Proteins 0.000 claims 15
- 102100032702 Protein jagged-1 Human genes 0.000 claims 15
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 14
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 14
- 102100031934 Adhesion G-protein coupled receptor G1 Human genes 0.000 claims 12
- 102100040006 Annexin A1 Human genes 0.000 claims 12
- 102100025215 CCN family member 5 Human genes 0.000 claims 12
- 102100026252 Calcium/calmodulin-dependent protein kinase II inhibitor 1 Human genes 0.000 claims 12
- 102100038445 Claudin-2 Human genes 0.000 claims 12
- 101000775042 Homo sapiens Adhesion G-protein coupled receptor G1 Proteins 0.000 claims 12
- 101000959738 Homo sapiens Annexin A1 Proteins 0.000 claims 12
- 101000934220 Homo sapiens CCN family member 5 Proteins 0.000 claims 12
- 101000913913 Homo sapiens Calcium/calmodulin-dependent protein kinase II inhibitor 1 Proteins 0.000 claims 12
- 101000882901 Homo sapiens Claudin-2 Proteins 0.000 claims 12
- 101001077604 Homo sapiens Insulin receptor substrate 1 Proteins 0.000 claims 12
- 101000628954 Homo sapiens Mitogen-activated protein kinase 12 Proteins 0.000 claims 12
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 claims 12
- 102100026932 Mitogen-activated protein kinase 12 Human genes 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 102100029393 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4 Human genes 0.000 claims 9
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 9
- RSNPAKAFCAAMBH-UHFFFAOYSA-N 3-(5-amino-2-methyl-4-oxoquinazolin-3-yl)piperidine-2,6-dione Chemical compound CC1=NC2=CC=CC(N)=C2C(=O)N1C1CCC(=O)NC1=O RSNPAKAFCAAMBH-UHFFFAOYSA-N 0.000 claims 9
- 102100035683 Axin-2 Human genes 0.000 claims 9
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 9
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 claims 9
- 101001125981 Homo sapiens 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase delta-4 Proteins 0.000 claims 9
- 101000874569 Homo sapiens Axin-2 Proteins 0.000 claims 9
- 101000990912 Homo sapiens Matrilysin Proteins 0.000 claims 9
- 101000661819 Homo sapiens Serine/threonine-protein kinase 17B Proteins 0.000 claims 9
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 9
- 102100030417 Matrilysin Human genes 0.000 claims 9
- 102100037959 Serine/threonine-protein kinase 17B Human genes 0.000 claims 9
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 9
- 101710168942 Sphingosine-1-phosphate phosphatase 1 Proteins 0.000 claims 9
- 102100030684 Sphingosine-1-phosphate phosphatase 1 Human genes 0.000 claims 9
- 239000013078 crystal Substances 0.000 claims 9
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 9
- 229960004942 lenalidomide Drugs 0.000 claims 9
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 9
- 229960000688 pomalidomide Drugs 0.000 claims 9
- 239000012453 solvate Substances 0.000 claims 9
- 229960003433 thalidomide Drugs 0.000 claims 9
- 239000013068 control sample Substances 0.000 claims 8
- 230000004043 responsiveness Effects 0.000 claims 6
- 102000001708 Protein Isoforms Human genes 0.000 claims 4
- 108010029485 Protein Isoforms Proteins 0.000 claims 4
- 239000012472 biological sample Substances 0.000 claims 4
- 101000596771 Homo sapiens Transcription factor 7-like 2 Proteins 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000009257 reactivity Effects 0.000 claims 1
- 230000004044 response Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586672P | 2012-01-13 | 2012-01-13 | |
| US61/586,672 | 2012-01-13 | ||
| PCT/US2013/021197 WO2013106686A1 (en) | 2012-01-13 | 2013-01-11 | Biomarkers for the treatment of hepatocellular carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015504677A JP2015504677A (ja) | 2015-02-16 |
| JP2015504677A5 true JP2015504677A5 (cg-RX-API-DMAC7.html) | 2016-03-03 |
Family
ID=47604231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014552323A Pending JP2015504677A (ja) | 2012-01-13 | 2013-01-11 | 肝細胞癌治療のためのバイオマーカー |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US8901110B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2802877A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2015504677A (cg-RX-API-DMAC7.html) |
| CN (1) | CN104737021A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2013202104B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2871535A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2014008388A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013106686A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CL2007002752A1 (es) | 2006-09-26 | 2008-07-11 | Celgene Corp Soc Organizada Ba | Compuestos derivados de 3-(4-oxo-4h-quinazolin-3-il)-piperidina-2,6-diona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar o prevenir enfermedades tales como cancer, dolor, degeneracion macular, trastorno pulmonar, tr |
| PE20140983A1 (es) | 2011-03-11 | 2014-08-25 | Celgene Corp | Formas solidas de 3-(5-amino-2-metil-4-oxo-4h-quinazolin-3-il)-piperidin-2,6-diona, y sus composiciones farmaceuticas y sus usos |
| JP2015531776A (ja) | 2012-09-04 | 2015-11-05 | セルジーン コーポレイション | ３−（５−アミノ−２−メチル−４−オキソキナゾリン−３（４ｈ）−イル）ピペリジン−２，６−ジオンのアイソトポログ及びその製造方法 |
| WO2015085172A2 (en) * | 2013-12-06 | 2015-06-11 | Celgene Corporation | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers |
| CN103645259B (zh) * | 2013-12-12 | 2015-03-11 | 深圳海王药业有限公司 | 一种同时测定泊马度胺及其有关物质的方法 |
| JP2017533727A (ja) * | 2014-10-13 | 2017-11-16 | セルジーン コーポレイション | 固形腫瘍の治療方法及び免疫調節療法への臨床的感度の予測因子としてのバイオマーカーの使用 |
| US10537585B2 (en) | 2017-12-18 | 2020-01-21 | Dexcel Pharma Technologies Ltd. | Compositions comprising dexamethasone |
| CN108048568B (zh) * | 2017-12-25 | 2021-02-02 | 贵州省人民医院 | Plcd4基因作为胃腺癌转移诊断标志物的用途 |
| CN109266747B (zh) * | 2018-09-21 | 2021-07-27 | 中国医学科学院北京协和医院 | 与i型神经纤维瘤合并脊柱畸形病相关gpr56及其应用 |
| JP2022513349A (ja) * | 2018-10-14 | 2022-02-07 | ランタン ファーマ インコーポレイテッド | イルジンおよびバイオマーカーを使用した固形腫瘍癌の治療方法 |
| WO2020107115A1 (en) * | 2018-11-29 | 2020-06-04 | Trillium Therapeutics Inc. | Biomarkers for cd47 blockade therapy |
| CN116064810A (zh) * | 2022-11-10 | 2023-05-05 | 杭州医学院 | CD24作为Hippo通路失活亚型肝细胞癌生物标志物的应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1166651C (zh) * | 2001-06-08 | 2004-09-15 | 北京大学药学院 | 具有抗炎和抗肿瘤作用r-双或糖苯丙异硒唑取代化合物 |
| US7803783B2 (en) * | 2002-12-06 | 2010-09-28 | The Board Of Trustees Of The Leland Stanford Junior University | Use of WNT inhibitors to augment therapeutic index of chemotherapy |
| WO2011109237A2 (en) * | 2010-03-02 | 2011-09-09 | Emory University | Uses of noscapine and derivatives in subjects diagnosed with fap |
-
2013
- 2013-01-11 AU AU2013202104A patent/AU2013202104B2/en not_active Ceased
- 2013-01-11 CA CA2871535A patent/CA2871535A1/en not_active Withdrawn
- 2013-01-11 WO PCT/US2013/021197 patent/WO2013106686A1/en not_active Ceased
- 2013-01-11 JP JP2014552323A patent/JP2015504677A/ja active Pending
- 2013-01-11 US US13/740,012 patent/US8901110B2/en active Active
- 2013-01-11 MX MX2014008388A patent/MX2014008388A/es unknown
- 2013-01-11 EP EP13701319.9A patent/EP2802877A1/en not_active Withdrawn
- 2013-01-11 CN CN201380014334.8A patent/CN104737021A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504677A5 (cg-RX-API-DMAC7.html) | ||
| IL278381B1 (en) | Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers | |
| JP2016500110A5 (cg-RX-API-DMAC7.html) | ||
| Lin et al. | Endostatin and kidney fibrosis in aging: a case for antagonistic pleiotropy? | |
| Wang et al. | The non-canonical role of vascular endothelial growth factor-C axis in cancer progression | |
| Golubnitschaja et al. | Liver metastatic disease: new concepts and biomarker panels to improve individual outcomes | |
| JP2016534660A5 (cg-RX-API-DMAC7.html) | ||
| JP2011501176A5 (cg-RX-API-DMAC7.html) | ||
| IL247111B1 (en) | Preventive or therapeutic agent for kidney disease | |
| Yue et al. | Rnd3 haploinsufficient mice are predisposed to hemodynamic stress and develop apoptotic cardiomyopathy with heart failure | |
| Yang et al. | Pharmaco-transcriptomic correlation analysis reveals novel responsive signatures to HDAC inhibitors and identifies Dasatinib as a synergistic interactor in small-cell lung cancer | |
| WO2015100459A3 (en) | Biomarker profiles for predicting outcomes of cancer therapy with erbb3 inhibitors and/or chemotherapies | |
| JP2014517025A5 (cg-RX-API-DMAC7.html) | ||
| MX2014008388A (es) | Biomarcadores para el tratamiento de carcinoma hepatocelular. | |
| Aryal et al. | A switch in the dynamics of intra-platelet VEGF-A from cancer to the later phase of liver regeneration after partial hepatectomy in humans | |
| Shin et al. | Different effects of prolonged β-adrenergic stimulation on heart and cerebral artery | |
| He et al. | Double-positive expression of high-mobility group box 1 and vascular endothelial growth factor C indicates a poorer prognosis in gastric cancer patients | |
| Kato et al. | Lactate dehydrogenase and hemolysis in sickle cell disease | |
| Kotelevets et al. | The Rac1 splice form Rac1b favors mouse colonic mucosa regeneration and contributes to intestinal cancer progression | |
| JP2010502979A5 (cg-RX-API-DMAC7.html) | ||
| JP2015528562A5 (cg-RX-API-DMAC7.html) | ||
| Olsen Hult et al. | EP receptor expression in human intestinal epithelium and localization relative to the stem cell zone of the crypts | |
| Huang et al. | HBx-related lncRNA Dreh inhibits hepatocellular carcinoma metastasis by targeting the intermediate filament protein vimentin | |
| Yamana et al. | Blood biological markers for prediction of escitalopram response in patients with major depressive disorder: preliminary study | |
| Diehl | Developmental morphogens & recovery from alcoholic liver disease |